Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P17931 (
galectin-3
)
2,860
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Galectin-3
is an important modulator of several biological functions. It has been implicated in numerous disease conditions, particularly in the long-term complications of diabetes because of its ability to bind the advanced glycation/lipoxidation end products that accumulate in target organs and exert their toxic effects by triggering proinflammatory and prooxidant pathways. Recent evidence suggests that
galectin-3
may also participate in the development of obesity and type 2 diabetes. It has been shown that
galectin-3
levels are higher in obese and diabetic individuals and parallel deterioration of glucose homeostasis. Two studies in
galectin-3
knockout mice fed a high-fat diet (HFD) have shown increased adiposity and adipose tissue and systemic inflammation associated with altered glucose homeostasis, suggesting that
galectin-3
negatively modulates the responsiveness of innate and adaptive immunity to
overnutrition
. However, these studies have also shown that impaired glucose homeostasis occurs in
galectin-3
knockout animals independently of obesity. Moreover, another study reported decreased weight and fat mass in HFD-fed
galectin-3
knockout mice. In vitro,
galectin-3
was found to stimulate differentiation of preadipocytes into mature adipocytes. Altogether, these data indicate that
galectin-3
deserves further attention in order to clarify its role as a potential player and therapeutic target in obesity and type 2 diabetes.
...
PMID:Role of Galectin-3 in Obesity and Impaired Glucose Homeostasis. 2677 Jun 60